logo
Wales Air Ambulance miss 550 patients amid rural location row

Wales Air Ambulance miss 550 patients amid rural location row

BBC News7 days ago
Hundreds of patients were missed by the Wales Air Ambulance over the past two years because resources were in the wrong place at the wrong time, the charity has claimed.Chief executive Sue Barnes said the poor road network around two bases in Welshpool, Powys, and Caernarfon, Gwynedd, along with a lack of overnight coverage, meant resources were under-utilised and must be merged on a new site.She said 551 patients treated by the ambulance service in the two years could not get an additional air ambulance response.Plans to merge the two bases have met stiff opposition from campaigners who said the strength of feeling had only deepened, despite their failed legal challenge to stop it.
The Wales Air Ambulance has another two bases - in Dafen, Carmarthenshire, and Cardiff.Each base has a helicopter and car but only Cardiff is operational 24 hours a day, the others run 07:00-19:00 or 08:00-20:00.
Ms Barnes said a 2020 audit revealed "we were missing a significant number of patients" in mid and north Wales, mostly in the evenings and overnight.From 2022-2024, of the 632 people who met the criteria for an air ambulance, the charity only saw 81.This compared to 983 in south Wales.Analysis showed there were 360 shifts between January 2023 and December 2024 where no patients were seen by crews in Welshpool and Caernarfon, compared to 32 in Cardiff and Dafen.Ms Barnes said "far and away the biggest driver of that disparity" was the staffing hours, but poor road networks around bases was also a factor."Now, that's not good enough... You can see why we felt that the inequity in the service was something that we needed to deal with," she added.
Ms Barnes said using the helicopter was the default choice in rural areas, but "increasingly we see our aircraft dragged in" to more urban areas in north-east Wales that were "very well-suited to a road response".Plans to have helicopters and cars based along the A55 from 2026 would allow them to reserve aircraft for more rural emergencies, she said.Bob Benyon from Welshpool, who has been heavily involved in a campaign to save the base, said he believed Wales Air Ambulance were "just moving the unmet need from one area to another".With no A&E nearby, he said the strength of support in the area was due to "the fact that we need a pre-hospital care system on hand, a few minutes away".
Some fundraisers previously suggested they would pull their support if the Welshpool site was closed.Mr Benyon said it was down to people to "follow their moral conscience" but he felt many people may be less willing to support it if the local base closed.
The charity argues that focusing on response times and the perception that it replaces a hospital fundamentally misunderstood its role."We're not a first responder role," said Ms Barnes. "In virtually every instance we attend, the ambulance service will get there before us."She also said it was not a given that the air ambulance would even have come from the nearest base and the emphasis now was on treating people at the scene."The overwhelming element is having access to the crew and the right skills, not the minutes and seconds that I think people sometimes think that matters."
Derwyn Jones has been a critical care practitioner for six years, mainly based at Caernarfon until his recent move to south Wales."If I'm bluntly honest it's a lot busier in south Wales and I feel within this role we need to practise our skillset to maintain competence," he said.He described the role as "a bit of a jack of all trades" covering aspects of A&E work, intensive care and anaesthetic departments, all by the side of the road.Part of his role includes shifts in the 999 control centre to pick out calls eligible for the emergency medical retrieval and transfer service (EMRTS), the specialist crew onboard the air ambulance aircraft and cars."It's really opened my eyes in the last few months, how much we are actually missing in the mid and north," he said.
Treatment has also changed, meaning response times are "not so much of an issue" with paramedics providing "a first wave of care," followed by EMRTS.Alongside critical care practitioners are highly-trained consultants who cover the shifts on a rota basis in addition to their NHS hospital roles, each of them a specialist in "pre-hospital emergency medicine".Mr Jones said since the EMRTS team joined the air ambulance service in 2015, "we've reduced mortality and morbidity from blunt trauma by 37%".Teams carry general anaesthetic and can even do open heart surgery, but ensuring the patient is taken to the most appropriate hospital is another vital part.In the past, patients would be taken to a nearby hospital and have a CT scan before it was known if they needed to be moved to a major trauma centre.Mr Jones said that could take up to six hours, whereas now "if we do take that 20 minutes longer to get to scene, they are still within our major trauma centre within an hour and a half - with the addition of having critical care on the roadside and in flight or in the car".
In the past, patients would be taken to a nearby hospital and have a CT scan before it was known if they needed to be moved to a major trauma centre.Mr Jones said that could take up to six hours, whereas now "if we do take that 20 minutes longer to get to scene, they are still within our major trauma centre within an hour and a half - with the addition of having critical care on the roadside and in flight or in the car".About 13 calls a day - 1% of the total calls - to the Welsh Ambulance Service are eligible for this specialist care.In July 2021 Laura Davies' husband Arwel and seven-year-old daughter Sofia were among them when they were involved in a crash not far from their home in Llanwrda, Carmarthenshire.Air ambulances from Cardiff and Welshpool were sent, along with a road crew from Dafen, but Arwel died at the scene.Laura asked if her husband would have been saved if he had made it to hospital and, in talks with the after-care team, she said she was able to understand the treatment he got at the scene "was the same as any hospital could have delivered".She added: "It was a huge comfort, it does help process the loss and certainly helps answer lots of questions I had."She said the empathy of the "real life superheroes" was part of the reason she got involved as a charity trustee.While medical staff are supplied by NHS Wales, funding for everything else is done by the Wales Air Ambulance charity."The care that was extended to myself and my daughter when we were transported to the Heath [hospital in Cardiff] was incredible."I was overwhelmed, I was terrified and they literally just held my hand through the process."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI chatbots ‘highly vulnerable' to repeating false medical information, experts warn
AI chatbots ‘highly vulnerable' to repeating false medical information, experts warn

The Independent

time22 minutes ago

  • The Independent

AI chatbots ‘highly vulnerable' to repeating false medical information, experts warn

AI chatbots are frequently prone to repeating false and misleading medical information, according to new research. Experts have warned of a 'critical need' for stronger safeguards before the bots can be used in healthcare, adding models not only repeated untrue claims but also 'confidently' expanded on them to create explanations for non-existent medical conditions. The team from the Mount Sinai School of Medicine created fictional patient scenarios, each containing one fabricated medical terms such as a made-up disease, symptom, or test, and submitted them to leading large language models. In a study published in journal Communications Medicine, they said that the chatbots 'routinely' expanded on the fake medical detail, giving a 'detailed, decisive response based entirely on fiction'. But their research also found that by adding one small prompt reminding the model the information provided might be inaccurate, errors could be reduced 'significantly'. 'Our goal was to see whether a chatbot would run with false information if it was slipped into a medical question, and the answer is yes,' said co-corresponding senior author Eyal Klang, MD, from the Icahn School of Medicine at Mount Sinai. 'Even a single made-up term could trigger a detailed, decisive response based entirely on fiction. 'But we also found that the simple, well-timed safety reminder built into the prompt made an important difference, cutting those errors nearly in half. That tells us these tools can be made safer, but only if we take prompt design and built-in safeguards seriously.' Co-author Dr Girish Nadkarni said the solution wasn't to 'abandon AI in medicine' but to 'ensure human oversight remains central'. The team hope their work can help introduce a simple 'fake-term' method for tech developers to use in testing medical AI systems. 'Our study shines a light on a blind spot in how current AI tools handle misinformation, especially in health care,' he said. 'It underscores a critical vulnerability in how today's AI systems deal with misinformation in health settings. 'A single misleading phrase can prompt a confident yet entirely wrong answer. The solution isn't to abandon AI in medicine, but to engineer tools that can spot dubious input, respond with caution, and ensure human oversight remains central. We're not there yet, but with deliberate safety measures, it's an achievable goal.' It comes after research last year showed many popular AI chatbots, including ChatGPT and Google's Gemini, lack adequate safeguards to prevent the creation of health disinformation when prompted. They found several large language models consistently created blog posts on false information, including the claim suncream causes skin cancer, when asked.

US Senators Wyden, Warren launch probe into UnitedHealth's nursing home practices
US Senators Wyden, Warren launch probe into UnitedHealth's nursing home practices

Reuters

timean hour ago

  • Reuters

US Senators Wyden, Warren launch probe into UnitedHealth's nursing home practices

Aug 7 (Reuters) - U.S. Senators Ron Wyden and Elizabeth Warren are launching an investigation into UnitedHealth Group (UNH.N), opens new tab related to allegations that the company secretly paid nursing homes thousands in bonuses to cut hospital transfers of sick residents. In a letter dated August 6 to UnitedHealth CEO Stephen Hemsley, the senators called on the healthcare conglomerate to provide detailed information about its reported incentive programming and its impact on the nursing home residents. This follows a May report from the UK's Guardian that the company made secret payments to nursing homes, as part of a series of cost-cutting tactics that helped the company save millions but risked residents' health, according to an investigation carried out by the newspaper. "Nursing home residents and their families should not live in fear of a for-profit health care company withholding care when it is most critical," the senators said in the letter. They have sought a response from the company by September 8 about its hospitalization policies, directives related to care planning for nursing home residents enrolled in its institutional special needs plans (I-SNPs), marketing practices related to those plans and federal oversight related to them. The company said it has received the Senators' letter and will continue to educate its staff and share information on the I-SNP model and its proven benefit for seniors. The allegations stem from an article that misrepresents a program and the U.S. Department of Justice extensively reviewed these allegations and found no evidence of wrongdoing, UnitedHealth said on Thursday. UnitedHealth is also under investigation by the U.S. DoJ over its Medicare business, a U.S. government program that covers medical costs for individuals aged 65 and older and those with disabilities. The company said in July it is complying with both criminal and civil requests from the federal agency.

Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection
Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection

Reuters

time3 hours ago

  • Reuters

Lilly pill cuts body weight by 12.4% in trial, lagging Novo's Wegovy injection

Aug 7 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in a late-stage study, less than previous trial results for Novo Nordisk's ( opens new tab injectable obesity treatment Wegovy. Lilly shares were down 6.7% in premarket trading as the data failed to meet the high bar set by investors. U.S.-listed shares of Novo were up about 8%. "The goal was to create an oral pill that was convenient and can be made at huge scale, really, for the mass market, and had weight loss that was competitive with other single-acting GLP-1s. And that's what we've achieved," Lilly CEO David Ricks said on CNBC. "The key question all along wasn't, were we going to have 12.4 or 13.5% weight loss? The key question all along was, is it safe enough?" said Ricks, whose comments appeared to calm investors who had initially sent Lilly shares down around 14%. He added that the company hopes the drug can start to get approvals around the world at this time next year. Unlike injectable obesity drugs, which are peptides designed to mimic the appetite-controlling GLP-1 hormone, orforglipron is a small molecule pill that is easier to manufacture and package, said Kenneth Custer, president of Lilly's cardiometabolic health division. Lilly, whose injectable GLP-1 Zepbound competes directly with Wegovy, views the once-daily pill as a promising alternative to injections that could be used for early intervention and long-term disease management, Custer said. Patient preference also leans toward oral medications over injections. Several studies have shown that a significant portion of patients prefer pills due to convenience and a dislike of needles. "We have pretty big aspirations for how many patients orforglipron could help," he said of the once-daily pill. In the over 3,000-person study of overweight or obese adults with weight-related health issues, but not diabetes, those who received the highest 36-milligram dose of orforglipron on average shed 12.4% of their weight versus 0.9% for those who received a placebo. Patients on the 6 mg dose of the Lilly drug lost 7.8% of their weight. After early trial results, expectations were high for the drug to do better than Novo's Wegovy, said Barclays analyst Emily Field. "It's worse than Wegovy, so it's a shock." The rate of nausea for high-dose patients was 33.7%, while 24% experienced vomiting, compared with 10.4% and 3.5%, respectively, for the placebo group. At least two analysts said the tolerability profile of orforglipron was not as good as what was seen in a trial that tested the drug on diabetes patients. While we still see this as manageable, "rates of nausea and vomiting may be higher than investor expectations," BMO Capital Markets analyst Evan Seigerman said. Just over 10% of the high-dose patients dropped out of the trial due to adverse side effects. No liver safety issues were seen, Lilly said. At least three analysts said the market had been looking for orforglipron to match Wegovy's 14.9% weight loss over 68 weeks, as shown in a 2021 trial, with some expecting the pill to surpass Novo's popular drug. Novo and Lilly shareholder Markus Manns called the results a best case scenario for Novo. "The competitive threat from Lilly is suddenly much weaker than anticipated." Zepbound and Wegovy currently dominate the weight-loss market, which some analysts expect to reach $150 billion by the early 2030s. The U.S. Food and Drug Administration is reviewing a high-dose oral version of Wegovy for potential approval later this year. Novo said it helped overweight or obese adults lose 15% of their body weight in a late-stage trial. Lilly said orforglipron also lowered markers of heart disease risk, including cholesterol, triglycerides, and blood pressure, across all doses. Wegovy has been approved to reduce the risk of major heart problems, and Lilly last week released data showing the heart-protective qualities of diabetes treatment Mounjaro, which has the same main ingredient as Zepbound. Heart disease approvals would greatly enhance the likelihood of insurance coverage for weight-loss drugs. The company announced earlier this year that a Phase 3 study found that type 2 diabetes patients lost nearly 8% of their body weight after 40 weeks on orforglipron. Lilly has said it has begun manufacturing the drug in order to stockpile supply ahead of a commercial launch, which should help avoid shortages experienced when early demand for the injectables far outstripped supply. The full results from the Lilly-backed trial will be presented next month at a major European diabetes meeting, the Indianapolis-based drugmaker said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store